This clinical trial is focused on patients who have suffered from burns and require a specific type of surgery known as *excision-autograft surgery*. This procedure involves removing damaged skin and replacing it with healthy skin from another part of the body. The study aims to evaluate the effectiveness of using *systemic antibiotic prophylaxis* to prevent infections after surgery. The antibiotics being studied are *Piperacillin Tazobactam* and *Cefazolin*. These medications are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein.

Participants in the study will be randomly assigned to receive either the antibiotics or a placebo, which is a substance with no active medication. The main goal is to see if these antibiotics can reduce the risk of infections, such as *postoperative sepsis* and *autograft lysis*, which is when the new skin graft does not take hold and requires another graft. The study will monitor patients for any signs of infection within seven days after their surgery.

Throughout the study, researchers will also observe other outcomes, such as the overall recovery and healing process, the length of hospital stay, and any potential colonization by *multiresistant bacteria*. The study is designed to provide valuable information on the best ways to prevent infections in burn patients undergoing this type of surgery, ultimately aiming to improve patient care and outcomes.